On this basis, IL-1 pathway can be considered a shared pathogenic mechanism, and a single treatment that manages both diseases appears to be a promising option for improving the care of RA and T2D patients (Giacomelli et al., 2016). This evidence concerns the gene IL1B and rheumatoid arthritis.